Journal of Liver

SMC Laboratories Inc., Technoport Minami-Kamata Ota City, Tokyo, Japan

Publications

• Research Article   
  Leronlimab A Humanized Anti-CCR5 Monoclonal Antibody Ameliorates Hepatic Fibrosis in Two Preclinical Fibrosis Mouse Models
  Author(s): Melissa Palmer*, Taishi Hashiguchi, A. Cyrus Arman, Yuka Shirakata, Neil E. Buss and Jacob P. Lalezari
  
  Background: Chemokine Receptor Type 5 (CCR5) is expressed on Hepatic Stellate Cells (HSCs), which, together with fibroblasts, are major producers of extracellular matrix during liver fibrosis. Leronlimab is a humanized IgG4κ monoclonal antibody that binds to CCR5. The objective of the present study was to evaluate the antifibrotic effects of leronlimab in three independent preclinical studies using two mouse models of liver fibrosis. Methods: In Stelic Animal Model (STAM™) model 1, leronlimab was administered at doses of 5 or 10 mg/kg/week for 3 weeks. STAM model 2 was conducted as a confirmatory study to validate the antifibrotic effect observed with the 10 mg/kg/week dose in STAM model 1. In a third study, a Carbon Tetrachloride (CCl4)-induced liver fibrosis mouse model was used to evaluate leronlimab administered at 10 mg/kg/w.. View more»
  

  DOI: 10.35248/2167-0889.26.15.281

  Abstract HTML PDF